GlassScriptPhysician profile
Sandra Adair
NPI 1497784359
$2,229.84
in general payments reported to CMS, 2019-2025
32 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,138 · 2020: $211 · 2022: $141 · 2023: $20.74 · 2024: $401 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $241.53 | 2019 | |
| Lilly USA, LLC | $208.51 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $200.46 | 2019-2025 | |
| Pfizer INC. | $193.49 | 2019-2025 | |
| Novo Nordisk INC | $154.61 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $142.70 | 2019-2025 | Breztri, Farxiga |
| Stryker Corporation | $140.82 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.69 | 2019-2024 | Trintellix |
| Glaxosmithkline, LLC. | $99.03 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Phathom Pharmaceuticals, INC. | $98.10 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.73 | 2019-2025 | Xifaxan, Trulance |
| Allergan, INC. | $58.51 | 2019 | |
| Shire North American Group INC | $57.77 | 2019 | |
| Arbor Pharmaceuticals, INC. | $38.59 | 2019 | |
| Dynavax Technologies Corporation | $38.57 | 2024-2025 | Heplisav-B |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $36.39 | 2024-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $35.06 | 2019-2025 | Veozah |
| Corium, LLC | $34.39 | 2025 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.18 | 2019-2020 | |
| Wright Medical Technology, INC. | $21.86 | 2019 | |
| Boston Scientific Corporation | $20.74 | 2023 | Wavewriter Alpha Prime 16 |
| Neos Therapeutics, LP | $18.98 | 2020 | |
| Verity Pharmaceuticals INC. | $18.61 | 2024 | Tlando |
| Alfasigma USA, INC. | $16.45 | 2020 | |
| Genentech USA, INC. | $15.80 | 2019 | |
| Currax Pharmaceuticals LLC | $15.70 | 2025 | Contrave |
| Exact Sciences Corporation | $15.27 | 2024 | Cologuard Collection Kit |
| Dexcom, INC. | $14.69 | 2025 | Dexcom G6 Transmitter |
| Hikma Pharmaceuticals USA | $14.67 | 2024 | Ryaltris |
| Therapeuticsmd, INC. | $14.37 | 2019 | |
| Sanofi Pasteur INC. | $12.38 | 2019 | |
| Vivus LLC | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Adair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.